|
•
DOH Home
•
HSQA
•
Medical Marijuana Public Hearings
•
How you can Improve Patient Safety
•
Profession
Links (A-Z)
•
Contact Info
•
Glossary
of Terms

Access
Washington |
|
|
This frequently asked questions document will be updated periodically. If you
have a question, please submit it to
MedicalMarijuana@doh.wa.gov, and it may be added to this list.
|
|
Q. |
Does this draft rule
decriminalize marijuana?
|
| A. |
No.
State law is clear that medical use of marijuana is different from
non-medical or recreational use. |
|
Q.
|
How did the
department settle upon its proposed 60-day supply limit of 24
ounces?
|
| A. |
-
The limit is based on carefully considering federal programs,
published studies, and public input. We also reviewed
regulations from other states that allow medical use of
marijuana.
-
Patients in the federal government’s Compassionate
Investigational New Drug (IND) Program may have about 17.5
ounces of marijuana for a 60-day period. This amount is based on
smoking as the only method of use.
-
Many patients cannot tolerate smoking marijuana, and some
patients say they use marijuana in a variety of other ways. They
may smoke it, vaporize it, eat it, or make ointments, tea, and
bath-soaks with it.
-
Studies indicate that it takes more marijuana when using it in
forms other than smoking — such as eating or vaporizing.
-
Allowing 24 ounces as a 60-day supply is consistent with the
federal Compassionate IND program, allows for some alternative
use, provides patients and law enforcement with a clear number,
and fosters consistent regulation with Oregon.
|
|
Q. |
How did you
decide to use plant count instead of plant canopy?
|
|
A. |
-
The proposed rule allows for a maximum of six mature plants and
a maximum of 18 immature plants.
-
The department considered several options to address the issue
of marijuana plants, including plant canopy and plant counts.
-
Feedback from patients and law enforcement agreed that the rules
should provide clear direction on medical marijuana limits. In
fact, some ideas shared by the public included plant counts.
-
Law enforcement comments indicated that calculating plant canopy
would be much more difficult than plant count.
-
Using a plant count is also consistent with our neighboring
state. Oregon has the same plant count limits in place.
|
|
Q. |
What is the difference
between a mature plant and an immature plant? |
|
A. |
Immature plants are any marijuana plants that meet all three of the
following:
-
There are no flowers on the plant.
-
It is less than 12 inches tall.
-
It
is less than 12 inches in diameter
|
|
Q. |
Is it true that
doctors can recommend more or less than the designated limits? |
|
A. |
-
Yes. The limits are not absolute. State law allows physicians to
recommend more (or less) than the presumptive limits if they can
show a medical need.
-
Doctors and patients should work together to determine the best
amount of marijuana, even if it is under or over the proposed
amount.
|
|
Q. |
Will this rule
mean that patients cannot be prosecuted if they are within the
limits? |
|
A. |
No. Patients can still be criminally
prosecuted. That’s outside of Department of Health authority. |
|
Q. |
What specific
studies were considered to develop the 60-day supply amount? |
|
A. |
The Department of Health reviewed studies from
the federal medical marijuana program, the Drug Enforcement Agency,
the Dutch Office of Medicinal Cannabis, and medical and scientific
researchers, among others. |
|
|
Here is a selected list of studies reviewed: |
|
|
-
Chris Conrad, “Cannabis Yields and Dosage: A Guide to the
Production and Use of Medical Marijuana,” Safe Access Now,
August 2007.
-
Emmanuel Street, Paul Verbanck, and Isy Pelc, “Pharmacology and
Neurobiology of Cannabis,” International Conference on Cannabis,
February 25, 2002.
-
Ethan Russo, Mary Lynn Mathre, Al Byrne, Robert Velin, Paul J.
Bach, Juan Sanchez-Ramos, Kristin A. Kirlin, “Chronic Cannabis
Use in the Compassionate Investigational New Drug Program: An
Examination of Benefits and Adverse Effects of Legal Clinical
Cannabis,” Journal of Cannabis Therapeutics, Vol. 2(1), 2002.
-
Gregory T. Carter, Patrick Weyd, Muraco Kynasha-Tocha, and
Donald Abrams. “Medicinal Cannabis: Rational Guidelines for
Dosing,” IDrugs, Vol.7(5), 2004.
-
Office
of Medical Cannabis, “Medicinal Cannabis, Information for Health
Care Professionals,” Ministry of Health, Welfare and Sports,
Netherlands, June 2007.
-
Sunil K. Aggarwwal, Muraco Kyashna-Tocha, and Gregory T. Carter,
“Dosing Medical Marijuana: Rational Guidelines on Trial in
Washington State,” Medscape General Medicine On-Line Journal,
September 2007.
-
U.S. Department of Justice, National Institute on Drug Abuse,
and Drug Enforcement Administration, “Cannabis Yields,” 1992.
-
Jones, Reese T.; “Human Effects: An Overview”; National
Institute of Drug Abuse Research Monograph Series #31 -
Marijuana Research Findings 1980; US Department of Health
and Human Services; June 1980; pp 54-80.
|
|
Q. |
What happens next? |
|
A. |
-
The public can provide comments on the draft rules in writing,
by e-mail and regular mail, or in person at the rule hearing.
-
A rule hearing will be held in Tumwater on August 25, 2008.
-
After all comments by public and interested parties are
reviewed, a final rule will be filed.
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|